



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

18 January 2021

ANNOUNCEMENT




Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

OPERATIONS UPDATE ON FORTACIN™



The directors (the “**Directors**” or the “**Board**”) of Regent Pacific Group Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) wish to inform the shareholders of the Company and potential investors of the following update in respect of its operations in relation Fortacin™.

Taiwanese, Hong Kong and Macau Approval and Commercialisation Progress



Further to the last operations update issued by the Company on 11 January 2021, the Directors are pleased to report that Orient EuroPharma Co., Ltd. (“**OEP**”), the Group’s commercial strategic partner for Taiwan, Hong Kong Special Administrative Region (“**Hong Kong**”), Macau Special Administrative Region (“**Macau**”) and other select countries in Asia, has launched Fortacin™, the Group’s prescription treatment for premature ejaculation, for sale in Hong Kong from this month. OEP has also informed the Group that it expects to launch Fortacin™ in Macau in March 2021 and in Taiwan (its home market) in April 2021. The Group will generate a low teens royalty of OEP’s net sales of Fortacin™ in these markets.



This marks a pivotal moment for the Group in realising its strategic goal of offering Fortacin™, through OEP, in its home market of Hong Kong.

Jamie Gibson, Chief Executive Officer of the Company, said, “The launch of Fortacin™ in Hong Kong and the upcoming roll-outs of Fortacin™ in other Asian countries will further strengthen the Company’s leadership in premature ejaculation treatments across the region. More importantly, the Company, supported by its strong Asia coverage, is well-positioned in the near future to capture a major share of the fast-growing global market for premature ejaculation treatments.”

Chinese Approval and Commercialisation Progress

The Group is also pleased to inform shareholders that Wanbang Biopharmaceutical Group Co., Ltd., the Company’s commercial strategic partner for China, has appointed a leading contract research organisation to undertake the randomised clinical trial in China. The randomised clinical trial is due to commence in April / May 2021, subject to the approval from National Medical Products Administration.

Other Out Licensing Opportunities

The Group is in early discussions with a potential partner for “out licensing” the rights to Fortacin™ for Japan. While these developments are indeed exciting, it is not possible to determine with accuracy the timing of completion of such discussions, and no assurance can be given that negotiations will lead to a binding licencing agreement(s).

The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Executive Director

Directors of the Company:

James Mellon (*Chairman*)*

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe*

* *Non-Executive Directors*

Independent Non-Executive Directors

Hong Kong, 18 January 2021



Forward Looking Statements

This announcement, including any information included or incorporated by reference in this announcement, contains statements about the Company that are or may be forward looking statements. Such forward looking statements involve risks and uncertainties that could significantly affect results and are based on certain key assumptions. Many factors could cause actual results to differ materially from those projected or implied in any forward looking statement. Much of the risk and uncertainty relates to factors that are beyond the Company's abilities to control or estimate precisely, such as future market conditions and the behaviours of other market participants, and therefore undue reliance should not be placed on such statements. Neither the Company nor any of its associates or directors, officers, employees, managers, agents, representatives, partners, members, consultants or advisers: (i) provide any representation, warranty, assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statement will actually occur; nor (ii) assume any obligation to, and do not intend to, revise or update these forward looking statements, except as required pursuant to applicable law, The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "HK Listing Rules") or other applicable regulation. The Company disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law, the HK Listing Rules or other applicable regulation.

No Profit Forecasts or Estimates

No statement in this announcement is intended as a profit forecast or estimate for any period and no statement in this announcement should be interpreted to mean that earnings or earnings per share for the Company for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share for the Company. The Company does not undertake to update information contained in this announcement, except as required by applicable law, the HK Listing Rules or other applicable regulation.